iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 400.00K.
Subavaliada
O PE mais recente da empresa é -3.00, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 18.97M ações, um aumento de 37.14% em relação ao trimestre anterior.